SeattleGenetics®

Fact Sheet

FEBRUARY 15, 2017

Empowered THERAPIES • ANTIBODIES • SCIENCE

ADCETRIS®
brentuximab vedotin | for injection

Quick Facts

- An ADC that targets CD30, which is expressed in classical Hodgkin lymphoma (HL) and in systemic anaplastic large cell lymphoma (sALCL), an aggressive type of T-cell non-Hodgkin lymphoma. ADCETRIS is comprised of an anti-CD30 monoclonal antibody linked to a cell-killing agent using Seattle Genetics' proprietary ADC technology.
- Being developed in collaboration with Takeda Pharmaceutical Company Limited; Seattle Genetics has full commercialization rights in the U.S. and Canada, Takeda has exclusive rights in the rest of the world.
- Commercially available in more than 65 countries, including the United States, Canada, Japan and members of the European Union for relapsed classical HL and relapsed sALCL.
- First therapeutic approved in the U.S. for HL in more than 30 years and the only drug FDA-approved specifically for sALCL.
- Third ADCETRIS indication as classical HL post-autologous transplantation consolidation was approved by U.S. Food and Drug Administration in August 2015. We have also submitted a supplemental NDS for the AETHERA indication to Health Canada. Takeda received European Commission approval for this indication in July 2016.

Seattle Genetics is an emerging global multi-product biotechnology company that develops and commercializes innovative antibody-based therapies for the treatment of cancer. We are the industry leader in antibody-drug conjugates (ADCs), a technology designed to harness the targeting ability of antibodies to deliver cell-killing agents directly to cancer cells. In addition to one marketed product, we are advancing a deep product pipeline designed to address significant unmet medical needs.

ADCETRIS: Broad Global Development Plan

Our lead program, ADCETRIS® (brentuximab vedotin) is the first in a new class of ADCs and, in collaboration with Takeda Pharmaceutical Company Limited, is commercially available in more than 65 countries. To further expand the ADCETRIS opportunity, we are conducting a broad clinical development program evaluating its potential to become the foundation of treatment for CD30-expressing lymphomas, including Hodgkin lymphoma, cutaneous T-cell lymphoma and mature T-cell lymphomas. Across both corporate and investigator trials, ADCETRIS is in more than 70 clinical trials, including more than 50 in Hodgkin lymphoma.

Vadastuximab Talirine: Pivotal Phase 3 Program

We also are advancing vadastuximab talirine (SGN-CD33A; 33A), a novel ADC that is being evaluated in the pivotal phase 3 CASCADE trial for acute myeloid leukemia (AML). AML is a significant unmet need, as treatments have not meaningfully changed in more than four decades. 33A is targeted to CD33 which is expressed on most AML cells as well as in myelodysplastic syndrome (MDS), often a precursor to AML.

ADCs: Integral Part of Cancer Therapy

ADCETRIS and vadastuximab talirine are two of more than 20 ADCs in clinical development using our proprietary technology. We are also advancing enfortumab vedotin (ASG-22ME) for urothelial cancer under our collaboration with Astellas, and SGN-LIV1A for triple-negative breast cancer, as well as several other internal clinical and preclinical programs. Our deep product pipeline provides opportunities across hematologic malignancies and solid tumors.

Our ADC technology is also employed by collaborators who are advancing multiple programs using Seattle Genetics' proprietary approach to empowering antibodies. Through internal research and development, collaborations and scientific innovation, we are committed to improving treatment outcomes for patients.

ADVANCING INDUSTRY-LEADING ADC Technology

Empowering Antibodies, Targeting Cancer

Antibody-drug conjugates (ADCs) have become an integral part of cancer treatment by harnessing the specificity of monoclonal antibodies and the potency of cell-killing (cytotoxic) agents.

The key components of our proprietary ADC technology are the potent synthetic cytotoxic agents and the stable linkers that attach the cytotoxic agent to an antibody. The antibody is targeted against a specific tumor-associated receptor on cancer cell surfaces. Our linker systems release the cell-killing agent once inside the targeted cells. This approach is intended to spare non-targeted cells and reduce the toxic effects of traditional chemotherapy while enhancing antitumor activity.

We are conducting significant research activities to continue advancing our ADC technology and are committed to staying the leader in ADC development.

Auristatins

The lead group of cytotoxic agents that we have developed is a class of microtubule-disrupting agents called auristatins, including monomethyl auristatins E and F (MMAE and MMAF). In preclinical models, these auristatins are 100- to 1,000-fold more potent than traditional chemotherapy drugs.

PBDs

Our newest ADC technology uses a highly potent DNA binding agent called a pyrrolobenzodiazepine (PBD) dimer. The targeted antibody is attached to the PBD with our proprietary site-specific conjugation technology with engineered cysteines (EC-mAb). PBD dimers are significantly more potent than systemic chemotherapeutic drugs and the site-specific conjugation technology allows two uniform attachment sites of the cell-killing PBD agent to the antibody.



ADCs Are an Integral Part of Cancer Therapy

By targeting specific tumor-associated receptors on the surface of cancer cells, ADCs have the potential to spare non-targeted cells and reduce toxic side effects. Other approaches to cancer treatment target pathways inside the cell or activate immune cells. Various combinations of these novel modalities are likely to be the future of treatment in oncology. In addition to advancing our ADC research, we are applying our expertise in targets and antibodies to the area of immuno-oncology. We are conducting clinical trials of ADCETRIS in combination with nivolumab, a checkpoint inhibitor, as part of a collaboration with Bristol-Myers Squibb. We also have a collaboration and license agreement with Unum Therapeutics to develop and commercialize novel antibody-coupled T-cell receptor (ACTR) therapies. And, we are conducting clinical trials with SEA-CD40, a novel immuno-oncology agent using our sugar-engineered antibody technology.

Extending Our Opportunities through ADC Technology Collaborations

Collaborating with other leading biotechnology and pharmaceutical companies is a strategy that generates financial benefit for Seattle Genetics. It extends the reach of our technology into programs being developed by our collaborators, and in some cases, provides us with future pipeline opportunities through co-development or opt-in rights to new ADC product candidates.

Multiple licensing agreements for our proprietary ADC technology have generated more than $350 million to date and the potential for several billion in future milestone payments based on advancement of collaborator ADCs plus royalties.

Find more details on our ADC technology collaborator program at www.SeattleGenetics.com.

abbvie · astellas · BAYER · Celldex therapeutics · Genentech A Member of the Roche Group · Genmab · gsk GlaxoSmithKline · Pfizer · Progenics Pharmaceuticals

Deep Oncology Pipeline

Hodgkin Lymphoma (HL)		
Brentuximab vedotin	ECHELON-1: Frontline HL	Phase 3: Enrollment Complete
	Frontline HL in patients 60+ (+/- chemotherapy or nivolumab)	Phase 2: Enrolling
	Second-line HL (+ nivolumab, an immunotherapy)	Phase 2: Enrolling
Non-Hodgkin Lymphoma (NHL)		
Brentuximab vedotin	ALCANZA: Relapsed CD30-expressing cutaneous T-cell lymphoma	Phase 3: Full data reported at ASH 2016
	ECHELON-2: Frontline CD30-expressing mature T-cell lymphoma	Phase 3: Enrollment Complete
	Relapsed CD30-expressing diffuse large B-cell lymphoma	Phase 2: Enroll
	Relapsed NHL (+ nivolumab, an immunotherapy)	Phase 1/2: Enrolling
Denintuzumab mafodotin (SGN-CD19A)	Relapsed/refractory diffuse large B-cell lymphoma	Phase 2: Enrolling
	Frontline diffuse large B-cell lymphoma or follicular lymphoma	Phase 2: Enrolling
SEA-CD40	Relapsed hematologic malignancies	Phase 1: Enrolling
SGN-CD19B	Relapsed/refractory aggressive B-cell NHL	Phase 1: Enrolling
Leukemia & Myelodysplastic Syndrome (MDS)		
Vadastuximab talirine (SGN-CD33A)	CASCADE: Frontline acute myeloid leukemia (AML)	Phase 3: Enrolling
	Frontline MDS	Phase 1/2: Enrollling
	Frontline younger AML	Phase 1
	AML (monotherapy and +HMAs)	Phase 1
	Relapsed AML pre/post allo-transplant	Phase 1
SGN-CD123A	Relapsed/refractory AML	Phase 1: Enrolling
Solid Tumors		
Enfortumab vedotin* (ASG-22ME)	Metastatic urothelial cancer	Phase 1: Enrolling
SGN-LIV1A	Metastatic breast cancer	Phase 1: Enrolling
ASG-15ME*	Metastatic urothelial cancer	Phase 1: Enrolling
SEA-CD40	Advanced solid malignancies	Phase 1: Enrolling
SGN-2FF	Advanced solid tumors	Phase 1: Enrolling
Multiple Myeloma		
SGN-CD352A	Relapsed/refractory multiple myeloma	Phase 1: Enrolling
SGN-CD48A	Relapsed/refractory multiple myeloma	Preclinical

* Program being developed in collaboration with Astellas

SeattleGenetics®

SEATTLE GENETICS, INC.
21823 30TH DRIVE SOUTHEAST
BOTHELL, WASHINGTON 98021
www.SeattleGenetics.com

Senior Management Team

Clay B. Siegall, Ph.D.
PRESIDENT & CHIEF EXECUTIVE OFFICER

Eric L. Dobmeier
CHIEF OPERATING OFFICER

Jonathan Drachman, M.D.
CHIEF MEDICAL OFFICER AND EXECUTIVE VICE PRESIDENT, RESEARCH AND DEVELOPMENT

Vaughn B. Himes, Ph.D.
CHIEF TECHNICAL OFFICER

Todd E. Simpson
CHIEF FINANCIAL OFFICER

Darren Cline
EXECUTIVE VICE PRESIDENT, COMMERCIAL

Jean I. Liu, J.D.
GENERAL COUNSEL, EXECUTIVE VICE PRESIDENT, LEGAL AFFAIRS

Christopher Pawlowicz
EXECUTIVE VICE PRESIDENT, HUMAN RESOURCES

Elaine Waller, Pharm.D.
EXECUTIVE VICE PRESIDENT, REGULATORY AFFAIRS AND CLINICAL DEVELOPMENT OPERATIONS

Board of Directors

Clay B. Siegall, Ph.D.
PRESIDENT, CHIEF EXECUTIVE OFFICER AND CHAIRMAN OF THE BOARD OF DIRECTORS, SEATTLE GENETICS, INC.

Srinivas Akkaraju, M.D., Ph.D.
SENIOR ADVISOR, SOFINNOVA VENTURES

Felix J. Baker, Ph.D.
MANAGING PARTNER, BAKER BROTHERS INVESTMENTS

David W. Gryska
EXECUTIVE VICE PRESIDENT AND CHIEF FINANCIAL OFFICER, INCYTE CORPORATION

Marc E. Lippman, M.D.
KATHLEEN AND STANLEY GLASER PROFESSOR AND DEPUTY DIRECTOR, SYLVESTER COMPREHENSIVE CANCER CENTER, UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE

John A. Orwin
CHIEF EXECUTIVE OFFICER, RELYPSA, INC.

Nancy A. Simonian, M.D.
CHIEF EXECUTIVE OFFICER, SYROS PHARMACEUTICALS, INC.

Daniel G. Welch
EXECUTIVE PARTNER, SOFINNOVA VENTURES

Recent Corporate Highlights

- February 2017: Announced global license agreement with Immunomedics for sacituzumab govitecan (IMMU-132)
- January 2017: Enrolled first patient in phase 1 trial of our ninth clinical-stage program, SGN-CD352A, an ADC for multiple myeloma
- December 2016: Highlighted phase 1 data for novel antibody-drug conjugate SGN-LIV1A in patients with metastatic breast cancer at San Antonio Breast Cancer Symposium
- December 2016: Presentations at the 58th American Society of Hematology (ASH) Annual Meeting highlighted our expanding global leadership in the development of innovative antibody-drug conjugates; 18 abstracts accepted, and eight oral presentations, including full results of the phase 3 ALCANZA trial of ADCETRIS® (brentuximab vedotin) in cutaneous T-cell lymphoma and four oral presentations featuring data from clinical studies exploring vadastuximab talirine (SGN-CD33A) in acute myeloid leukemia
- November 2016: Received FDA Breakthrough Therapy Designation for ADCETRIS in mycosis fungoides and primary cutaneous anaplastic large cell lymphoma
- November 2016: Completed enrollment of phase 3 ECHELON-2 clinical trial evaluating ADCETRIS in frontline mature T-cell lymphoma
- October 2016: Highlighted promising enfortumab vedotin (ASG-22ME) and ASG-15ME phase 1 data in metastatic urothelial cancer at European Society for Medical Oncology (ESMO) Congress
- September 2016: Initiated clinical trial of novel ADC SGN-CD123A in relapsed/refractory acute myeloid leukemia (AML), our second clinical program in AML

SGEN Quick Facts

NASDAQ SYMBOL
SGEN

CASH AND INVESTMENTS
$619 million as of December 31, 2016

COMMON STOCK OUTSTANDING
Approximately 140 million shares

FISCAL YEAR END
December 31

YEAR FUNDED
1998

GLOBAL HEADQUARTERS
Bothell, WA USA

EUROPEAN HEADQUARTERS
Zug, Switzerland

INVESTORS
Peggy Pinkston, 425.527.4160
PPinkston@seagen.com

MEDIA
Brandi Robinson, 425.527.2910
BRobinson@seagen.com

TECHNOLOGY LICENSING
BusinessDevelopment@seagen.com

GENERAL INQUIRIES
Contact@seagen.com

FOLLOW US ON TWITTER
@SeattleGenetics

 Certain of the statements made in this fact sheet and elsewhere are forward looking. These statements are based on factors that involve risks and uncertainties, and actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include risks and uncertainties associated with fulfilling sales, marketing and distribution requirements; the acceptance of ADCETRIS in the marketplace; the status of reimbursement from third-party payors; risks inherent in clinical stage development and risks that our collaborators do not fulfill their obligations. For additional information on these and other factors that could affect Seattle Genetics' results, see the reports filed by the company with the SEC, which are available at www.sec.gov. Seattle Genetics disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.